Transplant/Artificial Liver
Liver Transplant - HCV
AASLD 2014: DAAs Show Good Cure Rates and Liver Function Improvement for Transplant Recipients with Recurrent HCV
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 25 November 2014 00:00
- Written by Liz Highleyman
A variety of interferon-free regimens containing the direct-acting antivirals sofosbuvir (Sovaldi), simeprevir (Olysio), and daclatasvir (Daklinza) led to high sustained virological response rates, often improved liver function, and were generally safe and reasonably well-tolerated by liver transplant recipients with hepatitis C recurrence, one of the most difficult populations to treat, according to several presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston.
AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Post-Transplant HCV Recurrence
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 25 November 2014 00:00
- Written by Liz Highleyman
An interferon-free regimen of sofosbuvir plus ledipasvir (Harvoni) taken with ribavirin for 12 or 24 weeks led to sustained virological response in nearly all HCV genotype 1patients with fibrosis or less-advanced liver cirrhosis, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston. Response rates fell for people with more severe cirrhosis and signs of liver decompensation, but still a majority were cured.
Increased Distance Reduces Likelihood of Liver Transplant
- Details
- Category: Liver Transplant - HBV
- Published on Friday, 04 April 2014 00:00
- Written by Liz Highleyman
Living and receiving health care further away from a transplant center was associated with lower chances of being wait-listed for or receiving a liver transplant, according to a study of U.S. veterans described in the March 26 edition of JAMA.
AASLD 2014: HIV Positive People Have High Survival Rates After Liver Transplants Due to HCC
- Details
- Category: Liver Transplant - HCV
- Published on Monday, 10 November 2014 00:00
- Written by Liz Highleyman
People with HIV -- most of whom were coinfected with hepatitis B or C -- generally had good outcomes after liver transplantation due to hepatocellular carcinoma (HCC), with 5-year survival rates similar to those of HIV negative transplant recipients and better than those of people who underwent other types of liver cancer treatment, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 26 November 2013 00:00
- Written by Liz Highleyman
Hepatitis C patients who took low-dose aspirin after liver transplantation experienced slower fibrosis progression, researchers reported at the AASLD Liver Meeting this month in Washington, DC. Two other studies showed that cenicriviroc -- a drug being developed for HIV treatment that blocks both CCR5 and CCR2 cell surface receptors -- had anti-inflammatory and anti-fibrotic activity in mice and rats.
More Articles...
- AASLD 2013: Hepatitis C Treatment Reduces Liver Cancer and Death, But Most Remain Untreated
- AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%
- AASLD 2013: Sofosbuvir Taken Before or After Liver Transplant Reduces HCV Recurrence
- Human Stem Cells Used to Create Functional Liver Cells in Mice
Web Design and Development by